Cliff Asness’s Terns Pharmaceuticals TERN Stock Holding History

Cliff Asness’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-176,773	Closed	-$9.32M	–	3964
2026 Q1	$9.32M	Buy	176,773 +130,449	+282%	+$5.36M	﹤0.01%	1374
2025 Q4	$1.87M	Buy	46,324 +6,140	+15%	+$142K	﹤0.01%	2160
2025 Q3	$302K	Buy	40,184 +3,210	+9%	+$20.5K	﹤0.01%	3079
2025 Q2	$138K	Buy	+36,974	New	+$115K	﹤0.01%	3128
2025 Q1	–	Sell	-16,868	Closed	-$93.4K	–	3198
2024 Q4	$93.4K	Buy	+16,868	New	+$114K	﹤0.01%	2771
2023 Q4	–	Sell	-17,014	Closed	-$85.6K	–	2445
2023 Q3	$85.6K	Sell	17,014 -1,049	-6%	-$6.66K	﹤0.01%	2241
2023 Q2	$158K	Buy	+18,063	New	+$211K	﹤0.01%	2107

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cliff Asness's TERN Position: Q2 2026 in Review

Cliff Asness sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 176,773 shares — an estimated $9.32M sold.

Cliff Asness first reported a position in TERN in Q2 2023 and held it in 7 quarters. The position peaked at $9.32M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Cliff Asness reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cliff Asness sold 176,773 Terns Pharmaceuticals shares in Q2 2026, an estimated $9.32M.
Cliff Asness first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 7 quarters.
Cliff Asness's Terns Pharmaceuticals position peaked at $9.32M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.